Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
10 participants
OBSERVATIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients who have been infected with HIV recently are considered to have acute, or early, HIV infection. During this period, viral load (level of HIV in the body) rises sharply to a high level at first but then decreases significantly on its own. Doctors are not sure why this decrease in viral load happens and how the body is able to accomplish this. In this study, patients with acute HIV infection will be monitored so that doctors can study their immune systems to try to learn more about this rise and fall in viral load.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Monitor Patients With Primary or Early HIV Infection
NCT00000911
Outcomes of Anti-HIV Therapy During Early HIV Infection
NCT00001093
Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection
NCT00789009
Acute HIV Infection Observational Study
NCT00296660
The Biology of HIV Transmission
NCT00001092
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cohort I (HIV-negative volunteers): At study entry a medical history and physical exam is performed, and volunteers complete a questionnaire. Blood samples are drawn weekly until Week 12, then at Weeks 14, 16, 20, and 24. Volunteers are followed for 24 weeks. Volunteers are offered the opportunity to participate in a lymphoid tissue substudy, which involves one to four sequential gut-associated lymphoid biopsies. Compensation for travel and for the inconvenience of study participation is provided.
Cohort II: At study entry a patient history and physical exam is performed, and volunteers complete a questionnaire. Volunteers with a rising plasma HIV RNA during the first three visits will have frequent sampling of blood and physical exams for two years. Volunteers continue to be followed thereafter once every 6 months through 5 years of study duration. Volunteers are offered the opportunity to participate in a lymphoid tissue substudy and/or the lymphoid kinetics substudy. These substudies require hospitalizations of 24 hours or less for tissue biopsies and glucose infusion. Compensation for travel and for the inconvenience of study participation is provided
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are at least 13 years old (consent of parent or guardian required if under 18).
* Have no active infections or cancer.
* Are HIV-negative.
Volunteers may be eligible for Cohort II of this study if they:
* Are at least 13 years old (consent of parent or guardian required if under 18).
* Have acute or early HIV infection. The stage of HIV infection will depend on the results of certain lab tests.
* Agree not to take anti-HIV drugs the first 4 weeks of the study.
Exclusion Criteria
* Weigh less than 45 kg (99 pounds).
* Have begun anti-HIV therapy.
* Are pregnant or breast-feeding.
13 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susan Little
Role: PRINCIPAL_INVESTIGATOR
Diane Havlir
Role: PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Joanne Santangelo
San Diego, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AEHIV 008
Identifier Type: -
Identifier Source: secondary_id
AIEDRP AI-05-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.